Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

NCT03060720 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03060720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03060720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
Lead sponsor
Dana-Farber Cancer Institute
Phase
Observational
Overall status
Active, not recruiting
Start date
February 24, 2017
Completion date
February 29, 2028
Enrollment
271 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer